IM-83 CAR-T cell therapy

N/A

Report date: 2024/01/02 15:18:01

Base Information

Drug NameIM-83 CAR-T cell therapy
Drug Alias Nameanti-GPC3 CAR-T cellsIM-83IM83
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Glypican-3
TargetsGlypican-3
Therapy Area/IndicationsLiver NeoplasmsCarcinoma, HepatocellularOsteosarcoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesImunopharm Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImunopharm Technology Co LtdBeijing Yimiao Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, HepatocellularOsteosarcoma
Inactive IndicationsLiver NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A